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zimilide: Another Effort
o Prevent Implantable
ardioverter-Defibrillator
hocks and Their Sequelae
hy it Is Important and How it Works*
avid S. Cannom, MD, FACC, Brett Gidney, MD
os Angeles, California
ver the past decade, a series of randomized clinical trials
sing the implantable cardioverter-defibrillator (ICD) have
emonstrated a reduced mortality compared with that of the
est medical therapy in selected populations with ejection
raction (EF) 40%. Only patients with a low EF due to
ecent acute myocardial infarction or recent coronary bypass
urgery do not benefit as seen in prior trials. Subsequent
CD shocks remain of great interest to investigators since
evice therapies are associated with significant patient
orbidity and mortality.
See page 1076
Patients with ICDs receive frequent shocks from their
evices. In the AVID (Antiarrhythmic Versus Implantable
efibrillator) trial, there was a 46% incidence of shocks at 1
ear (1). In the MADIT II (Multicenter Automatic Defi-
rillator Implantation Trial II) study, during the 17.2-
onth follow-up of 719 subjects, 169 (24%) received
ppropriate and 83 (11.5%) received inappropriate ICD
herapy (2,3). ICD shocks have a negative impact on quality
f life including anxiety, panic, depression, and decreased
hysical and sexual activity. A meta-analysis shows that
sychological intervention reduces anxiety and depression
4). It is not surprising that the impact of ICD shocks is
elated to a patient’s personality type and social network (5).
The MADIT II study evaluated the effect of placebo
ersus ICD on total mortality in patients with coronary
rtery disease and an EF 30% (6). At 2 years, the total
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oard for CardioNet.ortality was reduced 31% by the ICD compared with that
een with medical therapy. A retrospective analysis of the
ADIT II study population showed that during the 2 years
f the trial 21% of patients were hospitalized for congestive
eart failure (CHF) (7). A higher number of patients in the
CD group required hospitalization (23%) compared with
he conventionally treated group (17%, p  0.02). The
ccurrence of an appropriate shock was a significant predic-
or of both CHF hospitalization and subsequent death. The
ffect of antitachycardia pacing (ATP) was not separately
nalyzed. The occurrence of an ICD shock and resultant
HF thus mitigated the mortality benefit of the ICD in the
ADIT II study. Possible explanations for this finding
nclude prolongation of life by effective ICD therapy allow-
ng more time for CHF to occur or, conversely, that cardiac
uscle and function are damaged by the ICD shock and
ause CHF.
It is essential to minimize ICD shocks for patient comfort
ven if a mortality benefit is uncertain. One-third of ICD
atients are treated with antiarrhythmic drugs after inser-
ion. A recent meta-analysis showed that amiodarone is
ore effective than a beta-blocker in reducing ICD shocks
8). Sotalol is no better than a beta-blocker (9). No
ntiarrhythmic drug is approved by the Food and Drug
dministration specifically as a therapy to reduce ICD
hocks. Lipid-lowering agents also reduce ICD shocks (10).
Sophisticated programming of ICDs reduces shocks.
ggressive ATP for ventricular tachycardia rates over 200
eats/min will reduce the number of shocks by 80% (11).
xtending the number of intervals to detect a ventricular
rrhythmia before delivering defibrillating therapy reduces
hocks because many arrhythmias self-terminate. Cardiac
blation as first-line prophylactic therapy to reduce shocks in
CD populations is surprisingly effective. The SMASH-VT
Substrate Mapping and Ablation in Sinus Rhythm to Halt
entricular Tachycardia) trial showed that patients ran-
omized to primary ablation after device insertion had
ppropriate ICD shocks reduced from 33% to 15% (12).
Azimilide is an investigational class III antiarrhythmic
rug with effects on the IKr and IKs potassium channels;
Kr block exhibits reverse use dependence (13). It has no
nown effect on cardiac hemodynamics. The current study
y Dorian et al. (14) in this issue of the Journal re-examines
he original SHIELD (Shock Inhibition Evaluation With
zimilide) study population. In the SHIELD study, 633
CD patients were randomized to determine if 75 or 125
g of azimilide reduced symptomatic ventricular arrhyth-
ias and ICD therapy compared with that in placebo (15).
zimilide reduced all appropriate therapies inclusive of
TP and shocks. In the current study, the data is reanalyzed
o determine if azimilide reduced emergency department
ED) visits and hospitalizations. The authors found that the
5 mg dose of azimilide significantly reduced “cardiac-
elated ED/hospitalizations” by 37% (Table 2 of Dorian et
l. [14]). Azimilide in a dose of 125 mg reduced this
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September 23, 2008:1084–5 Editorial Commenteasure by only 15%. However, the 125 mg dose of
zimilide reduced what are called—in a separate category in
able 2 of Dorian et al. (14)—“arrhythmic-related ED/
ospitalizations” by 31%, and the 75 mg dose reduced this
easure by 47%. It is difficult in the study to clarify whether
he ED visits and hospitalizations were for arrhythmias
nly, for CHF only, or for both.
The definitions used do not appear to be clearly pre-
pecified. Table 3 of Dorian et al. (14) states that only 21%
f the ED visits were for nonarrhythmic events. Are we to
resume this means for CHF alone without an arrhythmia?
verlapping or incomplete definitions hamper our under-
tanding of the data.
In this and other studies of ICD populations, the risk
actors for hospitalization or death include the presence of
dvanced heart failure and atrial fibrillation. Other studies
ave identified advanced renal failure, dual- versus single-
hamber device, and right ventricular pacing as contributing
o an increased mortality risk in ICD patients. These factors
re not considered here. It is unclear why azimilide has a
eneficial effect on any heart failure measure as it neither
liminates ICD shocks (in a statistically significant fashion)
or reduces the incidence of atrial fibrillation: either of these
ffects might reduce ED visits for any cardiac cause.
zimilide does reduce the incidence of ATP; while this may
e surrogate therapy for an ICD shock in this study, there
re no details about the specifics of this therapy that make
omparisons with published series possible. Azimilide had
o effect on mortality in the trial, although the follow-up
as only for 1 year.
The reasons for the differing clinical effects of 75 mg
ersus 125 mg of azimilide are clear neither in the study by
orian et al. (14) nor in the initial SHIELD study. Is there
ny reason we should expect a difference between 75 and
25 mg of azimilide on CHF given the known mechanisms
f action of azimilide?
This study is an interesting snapshot in the history of our
ttempt to decrease ICD shocks and their impact on clinical
utcomes. It confirms the importance of ICD therapy as a
ossible contributor to poor patient outcomes and shows
hat azimilide has a positive clinical effect albeit for unclear
easons. Perhaps, ultimately, the early application of cardiac
esynchronization therapy at the time of an initial clinical
hock or ATP episode will modify the now recognized and
isastrous short-term outcome of the ICD patient receiving
evice therapy (16).
eprint requests and correspondence: Dr. David S. Cannom,
ood Samaritan Hospital, 1245 Wilshire Boulevard, #703, Los
ngeles, California 90017. E-mail: dcannom@lacard.com.
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